Rational Combinations 360° 2019

Rational Combinations 360° is organized by The Conference Forum (TCF) and will be held from Jun 20 - 21, 2019 at Wyndham Philadelphia Historic District, Philadelphia, Pennsylvania, United States of America.

The ultimate goal is to foster a Summit environment that inspires positive change in immuno-oncology and support for all those involved in the movement.

Overview:
Industry and Academic Leaders Address Scientific, Clinical and Business Developments in IO Combination Strategies to Fight a Wider Range of Cancers.

The 4th annual Rational Combinations 360° program addresses business aspects, clinical advancements and scientific data in IO combination strategies. The rapid advancement in our understanding of human cancer immunity and immunotherapy combinations is nearly impossible for individual scientists to comprehend. Only together, as an engaged and interactive scientific community, can we hope to enable a patient’s immune system to eradicate cancer.

Rational Combinations 360° delivers three key benefits:
• Access to KOLs driving the science
• Partnership opportunities with all stakeholders in Immuno-Oncology & Combinations
• Presentations on the latest data affecting the science, clinical and business advancements in Immuno-Oncology Combinations

Key Topic Areas for 2019:
• Discovery / Preclinical Science
• Bispecifics
• Translational Science & Biomarkers
• Next Generation Cell Therapy
• Clinical Developments
• Operationalizing Combinations
• Business Aspects
• Emerging Technologies

Rational Combinations 360° provides the most up-to-date research, data and progress on combination developments to help IO stakeholders:
• Be at the forefront of the most relevant research and developments for IO combinations from key leadership who are at the pulse of cancer immunotherapy
• Foster collaboration amongst others working in all aspects of cancer immunotherapy by rounding up all stakeholders under one roof
• Receive the latest pre-clinical, translational and clinical data from academia and industry
• Better understand what assets are available for potential combinations that may be able to give patients more treatment options
• Create and prioritize combination strategies targeted toward specific tumor types
• Get key investor and analyst evaluations and insights on the IO combination landscape
• Learn about biomarker advancements, neoantigen approaches and more
• Obtain coverage on a wide range of emerging technologies

Additional details will be posted as soon as they are available.